Resumen de: US2022002805A1

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

Resumen de: US2021396753A1

This disclosure provides a method for analyzing peripheral blood leukocytes. In some embodiments, method may comprise: (a) labeling peripheral blood leukocytes isolated from a patient that has or is suspected of having inflammatory bowel disease (IBD) with a panel of distinguishably-labeled antibodies and (b) analyzing binding of the antibodies to the peripheral blood leukocytes. Kits for performing the method are also provided. Results from the analysis can be used to make a diagnosis of Crohn's disease or ulcerative colitis.

Resumen de: WO2021247548A1

Described herein are methods and systems for identifying subpopulations of patients having Crohn's disease, including populations at risk of developing stricturing or other severe disease, and populations susceptible to success or failure with surgical intervention. Further provided are therapies useful for treating subpopulations of patients having Crohn's disease.

Resumen de: WO2021243932A1

Disclosed is the use of phosphatidylserine as a target for treating inflammatory bowel disease. The phosphatidylserine can be used as a marker of inflammatory bowel disease and used for drug screening. Annexin A5 can trace and show the location and extent of inflammatory bowel disease lesions by means of the phosphatidylserine of the outer cell membrane, and can be used to treat inflammatory bowel disease. Better anti-inflammatory effects can be generated by mutating annexin A5.

Resumen de: US2021371931A1

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNF SF15 (or TL1A) and/or DcR3 genetic loci.

Resumen de: US2021369847A1

The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.

Resumen de: EP3913371A1

Method and kit for diagnosis of irritable bowel syndrome and irritable colon, comprising: a stool extraction system for preparation of a stool extract of substances of the gut-brain-axis, a derivatizing reagent for small biogenic amines; antibodies specific for derivatized tryptophan, serotonin, and GABA; and immunoassay reagents and buffers for combined determination of tryptophan, serotonin, and GABA. The method of in vitro diagnosis of irritable bowel syndrome (IBS) or irritable colon comprises a collecting a specimen of fresh stool; a transfer of the specimen into a stabilizing buffer; an extraction of the biogenic amines (neurotransmitters, neuroactive substances and tissue-active substances) and substances of the gut-brain axis; a combined quantitative analysis for tryptophan, serotonin and GABA, and optionally of histamine and kynurenic acid, to determine any imbalance of substances of the gut-brain-axis and for in vitro diagnosis of irritable bowel syndrome and/or irritable colon based on a comparison respective values and ranges in stools of healthy subjects.

Resumen de: EP3913364A1

Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

Resumen de: US2021355538A1

The present disclosure provides methods for assessing responsiveness or non-responsiveness to a therapeutic agent (e.g., steroid therapy, anti-TNF therapy or anti-integrin α4β7 therapy) in ulcerative colitis (UC) subjects based on gene signatures. The methods may further comprise identifying suitable treatment for the patient based on the gene signatures.

Resumen de: US2021355544A1

In one aspect, the present disclosure relates to a panel of biomarkers, a kit for detecting it, and its use in the detection of microsatellite instability (MSI) as well as non-invasive diagnosis, prognostic evaluation, selection of treatment or genetic screening of cancer, preferably colorectal cancer (such as bowel cancer), gastric cancer or endometrial cancer in a plasma sample. On the other hand, the present disclosure provides a method for detecting microsatellite instability (MSI) and disease-related gene mutations through plasma based on next-generation sequencing, and a device for implementing the method, especially the use of such detection method in the non-invasive diagnosis, prognostic evaluation, selection of treatment or genetic screening of patients with cancer, preferably colorectal cancer (such as bowel cancer), gastric cancer or endometrial cancer. This disclosure provides a plasma MSI detection method for the first time, which can determine the microsatellite instability of a sample with high accuracy and sensitivity.

Resumen de: WO2021224677A1

The present invention relates to compositions and methods for characterizing cancer. In particular, the present invention relates to compositions and methods for identifying bowel cancers at increased risk of metastasis.

Resumen de: WO2021222806A1

The present disclosure relates to a composition comprising a post-translationally modified Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) protein. The disclosure further relates to methods of preventing or treating Crohn's Disease and/or a condition resulting from Crohn's Disease in a subject. The disclosure further relates to methods for diagnosing and/or predicting severity of and/or treating Crohn's Disease in a subject. Also disclosed are methods for diagnosing inflammatory bowel disease in a subject and methods for diagnosing a pre-disease state of Crohn's Disease in a subject.

Resumen de: AU2020255035A1

The application provides new and improved methods for diagnosing IBS.

Resumen de: US2021332122A1

Provided herein are methods, systems and kits for use in identifying a subject with an increased risk of developing severe forms of inflammatory bowel disease (IBD), based at least in part, on an expression of one or more biomarkers detected in a biological sample obtained from the subject. Also provided are methods, systems and kits for treating, or optimizing the treatment for, the IBD based, at least in part, on the expression the one or more biomarkers. In some embodiments, the one or more biomarkers is angiotensin-converting enzyme 2 (ACE2), the host receptor for severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2).

Resumen de: US2021321936A1

The present disclosure relates to methods and devices to detect perforation of the bowel, for example, resulting from surgical procedures, such as laparoscopy, diagnostic procedures, such as colonoscopy, medical conditions, such as diverticulitis, and trauma. The present disclosure also relates to filtration systems and electrical connector assemblies for use in the methods and devices.

Resumen de: US2021324066A1

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

Resumen de: US2021325387A1

The present invention provides for a human cell atlas of the colon from healthy and diseased subjects. The atlas was obtained by single sequencing of about 117,000 cells. The present invention discloses novel markers for cell types. Moreover, genes associated with disease are identified in the colon and colon specific cell types. The invention provides for diagnostic assays based on gene markers and cell composition, as well as target cell types that express genes associated with disease. Finally, disclosed are novel cell types and methods of quantitating, detecting and isolating the cell types.

Resumen de: WO2021207725A1

The present invention relates to the field of short bowel syndrome. More specifically, the present invention provides methods and compositions useful for assaying for intestinal adaptation. In a specific embodiment, a method for treating a patient having SBS who is undergoing parenteral nutrition comprises the steps of (a) measuring lipocalin-2 (LCN2) in a sample obtained from the patient; and (b) reducing or eliminating parenteral nutrition if the measured level of LCN2 is below a control level or treating the patient with IL-22, a LCN2 inhibitor and/or an AHR agonist if the measured level of LCN2 is above the control level.

Resumen de: WO2021202649A2

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

Resumen de: WO2021195636A1

Provided herein is a method of treating an individual afflicted with an inflammatory bowel disease utilizing Candida abundance as a biomarker of responsiveness. The method comprises determining levels of Candida in a sample from the gastrointestinal tract of an individual, and if the level of Candida is higher than a reference level, identifying the individual as suitable for microbiota transplantation therapy (MTT), and optionally, administering to such an individual the MTT, and in individuals having gastrointestinal tract Candida levels lower than a reference level, increasing the Candida levels prior to prior to administration of MTT.

Resumen de: US2021278417A1

A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohns disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohns disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohns disease.

Resumen de: WO2014186750A2

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.

Resumen de: CN113316647A

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

Resumen de: US2021261651A1

Described are compositions and methods for treating inflammatory bowel diseases in a subject in need thereof. In certain aspects, the disclosure provides methods of treating a subject diagnosed with Irritable Bowel Disease (IBD), the method comprising administering to the subject an agent to reduce the number or pathogenic effects of a B. fragilis strain, wherein the subject is diagnosed with IBD by detecting the presence of the B. fragilis strain or a B. fragilis toxin in a biological sample of the patient.

Resumen de: WO2020081186A1

Described herein are methods of treatment of an inflammatory condition related to fungal immunity. The present disclosure relates to methods and systems for identifying patients suitable for treatment with active agents, as described herein. Further, described herein are various compositions for treating and identifying a subject in need of an active agent for treatment.